Precipio, inc. (PRPO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue, net of contractual allowances and adjustments

4,095

3,448

2,033

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

968

584

310

-

-

-

-

-

-

-

-

Net sales

3,127

2,864

1,723

-

-

-

-

-

-

-

-

NET SALES

-

-

-

1,557

1,929

1,240

27,544

31,480

31,971

20,048

22,023

Service revenue

-

-

1,317

-

-

-

-

-

-

-

-

Clinical research grants

-

-

114

-

-

-

-

-

-

-

-

Total cost of sales

2,908

2,639

1,431

1,762

1,940

2,175

16,790

18,348

13,534

10,284

10,418

Gross profit

219

225

292

-205

-11

-935

10,754

13,132

18,437

9,764

11,605

OPERATING EXPENSES:
Operating expenses

9,623

9,452

6,488

6,192

7,055

7,385

23,301

20,145

19,150

10,933

10,319

Impairment of intangible assets and goodwill

1,590

4,685

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

9,315

-

-

-

-

-

-

-

-

Research and development

-

-

-

1,422

1,853

2,249

3,212

2,491

2,218

2,305

3,182

Restructuring charges

-

-

-

-

-

-

-

-

41

138

0

Operating expenses

11,213

14,137

15,803

7,614

8,908

9,634

26,513

22,636

21,409

13,376

13,501

OPERATING LOSS

-10,994

-13,912

-15,511

-7,819

-8,919

-10,569

-15,759

-9,504

-2,972

-3,612

-1,896

OTHER INCOME (EXPENSE):
Interest expense, net

-473

-269

-2,324

-1,038

-724

-665

-642

-888

-958

-4

15

Warrant revaluation

416

1,918

-226

788

-205

455

-

-

-

-

-

Loss on modification of warrants

-1,128

-

-

-

-

-

-

-

-

-

-

Derivative revaluation

-415

267

-

-

-

-

-

-

-

-

-

Gain on settlement of liability, net

1,437

263

877

-

-

-

-

-

-

-

-

(Loss) gain on extinguishment of debt

-20

376

-1,391

-

-

-

-

-

-

-

-

Loss on extinguishment of convertible notes

-

-2,903

-

-

-

-

-

-

-

-

-

Loss on litigation

266

-

-

-

-

-

-

-

-

-

-

Gain on troubled debt restructuring

-

-

1,181

-

-

-

-

-

-

-

-

Loss on issuance of convertible notes

1,870

1,328

-

-

-

-

-

-

-

-

-

Loss on settlement of equity instruments

-

-385

-624

-

-

-

-

-

-

-

-

Merger advisory fees

-

-

2,676

-

-

-

-

-

-

-

-

Loss on sale/disposal of assets

-

-

-

-199

-14

-

0

0

-

-

-

Warrant revaluation

-

-

-

-

-

-

300

2,200

-

-

-

Expense on preferred stock

-

-

-

-

-

-

-

-

6,066

0

0

Warrant revaluation

-

-

-

-

-

-

-

-

0

0

-

Total other nonoperating income (expense)

-

-

-

-1

0

0

60

11

259

632

3

Total other expenses

-2,319

-2,061

-5,183

-450

-943

-210

-282

1,323

-6,765

628

18

LOSS BEFORE INCOME TAXES

-13,313

-15,973

-20,694

-8,269

-9,862

-10,779

-16,041

-8,181

-9,737

-2,984

-1,878

INCOME TAX BENEFIT

-70

-279

349

0

0

0

-54

146

45

150

42

LOSS FROM CONTINUING OPERATIONS

-

-

-

-8,269

-9,862

-10,779

-

-

-

-

-

INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES

-

-

-

653

-23,092

-3,163

-

-

-

-

-

NET LOSS

-13,243

-15,694

-20,694

-7,616

-32,954

-13,942

-15,987

-8,327

-9,782

-3,134

-1,920

Deemed dividends related to beneficial conversion feature of preferred stock and fair value of warrant down round features

-

4,222

12,431

-

-

-

-

-

-

-

-

Preferred dividends

-

-

84

393

1,324

1,144

-

-

-

-

-

TOTAL DIVIDENDS

-

4,222

12,515

-

-

-

726

660

1,010

0

0

NET LOSS AVAILABLE TO COMMON STOCKHOLDERS

-13,243

-19,916

-33,209

-8,009

-34,278

-15,086

-16,713

-8,987

-10,792

-3,134

-1,920

BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)

-2.33

-13.82

-7.16

-0.35

-2.78

-2.01

-2.30

-1.55

-2.62

-0.06

-0.04

BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

5,695

1,441

4,639

22,689

12,321

7,493

7,266

5,794

4,113

49,243

-

BASIC AND DILUTED WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

-

-

-

-

-

-

-

-

-

-

49,189

Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments

4,051

3,335

1,702

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

968

584

315

-

-

-

-

-

-

-

-

Net sales

3,083

2,751

1,387

-

-

-

-

-

-

-

-

Total cost of sales

2,908

2,549

-

-

-

-

-

-

-

-

-

Clinical research grants [Member]
Revenue, net of contractual allowances and adjustments

-

100

278

-

-

-

-

-

-

-

-

Total cost of sales

-

90

-

-

-

-

-

-

-

-

-

Other [Member]
Revenue, net of contractual allowances and adjustments

44

13

53

-

-

-

-

-

-

-

-